Stock 002755 BEIJING AOSAIKANG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Beijing Aosaikang Pharmaceutical Co., Ltd.

Equities

002755

CNE100001X92

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 29/04/2024 BST 		5-day change 1st Jan Change
11.18 CNY +3.71% Intraday chart for Beijing Aosaikang Pharmaceutical Co., Ltd. +14.08% +3.33%
04-28 Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-05 Beijing Aosaikang Pharma's Unit Gets Nod to Market Delafloxacin for Injection MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Beijing Aosaikang Pharma's Unit Gets Nod to Market Delafloxacin for Injection
MT
Aosaikang Pharmaceutical Registers Breast Cancer Drug
MT
Aosaikang Pharmaceutical's Unit Gets Nod for Two Drugs
MT
Aosaikang Pharmaceutical's Unit Gets Nod to Trial ASKC202 Tablets
MT
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Aosaikang Pharmaceutical's Unit Gets Nod to Test Gastric Cancer Drug
MT
Beijing Aosaikang Pharmaceutical Co., Ltd.(XSEC:002755) added to S&P Global BMI Index
CI
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Aosaikang Pharma's Unit Gets Nod to Amend Instructions for Heart Drug
MT
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Aosaikang Pharma Unit Registers Acid Reflux Drug in China
MT
Aosaikang Pharma Registers Three Drugs
MT
Aosaikang Pharma US Unit Gets Regulatory Nod For Anti-Tumor Drug Trial
MT
Beijing Aosaikang Pharmaceutical Co., Ltd.(XSEC:002755) dropped from S&P Global BMI Index
CI
Aosaikang Pharma Wins Nod to Market Variant of Pfizer’s Breast Cancer Drug
MT
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Beijing Aosaikang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Beijing Aosaikang Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2021, Payable on June 20, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002755 Stock
  4. News Beijing Aosaikang Pharmaceutical Co., Ltd.